PATENT CLAIM ANALYSIS

Application Number: 16075066
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "264110"]

Abstract:
The invention relates to the use of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof for the treatment of primary Sjögren's Syndrome.

Claim (Index 16):
A method according to  claim 8  wherein the administering step is b.i.d.

Metadata:
- Claim Count in Document: 24.0
- Percentile: 96.0
- Lexical Diversity: 1.17143
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13175050', '14151796', '12594364', '13741019', '11989038']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7774912357473855
- 35 USC 102 Novelty (BERT): 0.515230199417073
- Combined Prediction Score: 0.7512651321143543
- Mean Citation Score: 171.83873
- Max Citation Score: 184.94606
- Similarity Product: 90.40949199324608

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test